In the first direct comparison of two leading weight loss medications, tirzepatide produced significantly greater average weight loss than semaglutide in adults with obesity: 20.2% versus 13.7% over 72 weeks. For someone weighing 220 pounds, that translates to roughly 46 pounds lost with tirzepatide compared to 33 pounds with semaglutide, according to trial data published in the New England Journal of Medicine in 2025. But a bigger number on the scale doesn't automatically mean a better choice for every person. Understanding how these medications work, their side effects, and what happens to your muscle mass alongside fat loss can help you and your doctor make a more informed decision.

How Do Tirzepatide and Semaglutide Actually Work?

Both medications suppress appetite and help with weight loss, but they work through different mechanisms. Semaglutide, sold as Wegovy for weight management, activates a single appetite pathway called GLP-1 (glucagon-like peptide-1). This slows how fast your stomach empties food, increases feelings of fullness, and improves how your body handles blood sugar. Think of it as turning down one appetite dial.

Tirzepatide, marketed as Zepbound, activates two appetite pathways: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). The dual approach appears to produce stronger appetite suppression and greater weight loss on average. In the head-to-head trial, tirzepatide also reduced waist circumference more: 18.4 centimeters compared to 13.0 centimeters for semaglutide.

What Are the Key Differences in How You Take Them?

Both medications start at low doses and increase gradually over weeks to improve tolerability. Zepbound comes as a once-weekly injection, starting at 2.5 milligrams and increasing by 2.5-milligram increments every four weeks up to a maximum of 15 milligrams. Wegovy is available as a once-weekly injection or, as of 2026, a once-daily oral tablet. The pill version requires taking it on an empty stomach with just a sip of water, then waiting 30 minutes before eating or drinking anything else.

The injection form of Wegovy starts at 0.25 milligrams weekly and escalates to a maximum of 2.4 milligrams. If you miss a dose of Zepbound, you can take it within four days; otherwise, skip it and resume your regular schedule.

How to Compare Side Effects and Safety Profiles

• Gastrointestinal Effects: Both medications commonly cause nausea, diarrhea, vomiting, and constipation, especially during dose increases. These effects are typically temporary but can affect quality of life during the titration phase.
• Thyroid Safety Warning: Both carry a boxed warning about thyroid C-cell tumors observed in rodent studies. Neither medication should be used by people with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome.
• Serious but Uncommon Risks: Both medications warn about pancreatitis and gallbladder disease. Both also slow stomach emptying, which is important to disclose before anesthesia or deep sedation.
• Oral Contraceptive Interaction: Zepbound can reduce absorption of oral medications due to delayed stomach emptying. If you take birth control pills, your doctor may recommend switching to a non-oral contraceptive or adding a barrier method for four weeks after starting Zepbound and after each dose increase.

Do These Drugs Cause You to Lose Muscle Along With Fat?

This is the detail most weight loss comparisons overlook. Scale weight can drop for multiple reasons: fat loss, muscle loss, water loss, and glycogen depletion. A substudy using DEXA scans (a precise body composition imaging tool) from the Wegovy trial found that semaglutide reduced total fat mass and visceral fat (the dangerous fat around organs), but lean muscle mass also decreased in absolute terms. This matters because losing muscle can slow your metabolism and make it harder to maintain weight loss long-term.

The source material does not provide comparable muscle-loss data for tirzepatide, so it's unclear whether the dual-pathway approach preserves more muscle than semaglutide alone. This is an important question to discuss with your doctor, especially if you're also strength training.

Which Medication Has FDA Approval for Other Health Conditions?

Beyond weight loss, these medications have different approved uses. Wegovy is approved to reduce the risk of major adverse cardiovascular events (heart attack, stroke, cardiovascular death) in certain adults with established heart disease who also have obesity or are overweight. Zepbound is approved to treat moderate-to-severe obstructive sleep apnea in adults with obesity. If you have one of these conditions, that approval may influence which medication your doctor recommends.

What Do Real Trial Results Show?

The head-to-head comparison is the most direct evidence available. In a randomized phase 3b trial of adults with obesity but without type 2 diabetes, tirzepatide at the highest dose (15 milligrams) produced a mean weight loss of 20.2% compared to 13.7% for semaglutide at 72 weeks. In separate trials using each drug alone, tirzepatide showed a mean weight loss of 20.9% at the highest dose versus 3.1% for placebo, while semaglutide showed 14.9% weight loss versus 2.4% for placebo. The oral version of Wegovy showed similar results to the injection: 15.1% weight loss versus 2.4% for placebo.

Converting these percentages to pounds can make planning easier. For someone starting at 220 pounds, the trial-average weight loss would be approximately 33 pounds with Wegovy and 46 pounds with Zepbound. However, individual results vary widely, and these are averages across all trial participants.

How Should You Choose Between Them?

"Better on average" does not always mean "best for you." Your choice should depend on several factors: whether you have heart disease or sleep apnea (which might favor one medication's approved indication), your tolerance for injections versus pills, your access to oral contraceptives, and your personal response to side effects. Some people tolerate one medication better than the other, and some respond more dramatically to one than the other. Starting with a lower-cost or more accessible option and switching if needed is a reasonable approach. Working with your doctor to monitor not just scale weight but also body composition (fat versus muscle) will give you a clearer picture of whether your progress is sustainable.